Phase II study of sunitinib and irinotecan in patients with recurrent high-grade glioma (HGG)

Authors :: E. Montini
L. Poliani
G. Rangoni
Unita' di Oncologia Medica Gruppo Neuro-Oncologico Bresciano
Salvatore Grisanti
Francesca Consoli
Vittorio Ferrari
R. Liserre
Michela Buglione
Rebecca Pedersini
Edda Simoncini
Source :: Journal of Clinical Oncology. 28:e12537-e12537
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: e12537 Background: The prognosis of patients (pts) with recurrent HGG is poor with a median survival of 3 to 6 months. To date, no second line of treatment is recognized as standard. Enhanced angio...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Sunitinib
business.industry
Phases of clinical research
Irinotecan
Second line
Internal medicine
medicine
In patient
business
Median survival
medicine.drug
High-Grade Glioma

Tools